Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 12/20 | 1.00 |
| ▸ | PRKCG | P05129 | 11/20 | 1.00 |
| ▸ | PRKCB | P05771 | 11/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 11/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 10/20 | 1.00 |
| ▸ | PRKCH | P24723 | 10/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 10/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 8/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 8/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 8/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 0.73 |
| ▸ | CDK2 | P24941 | 2/20 | 0.67 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.67 |
| ▸ | CDK4 | P11802 | 1/20 | 0.67 |
| ▸ | CCND1 | P24385 | 1/20 | 0.67 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 3/20 | 0.63 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30958433 | 0.99 | PRKCA (0.98) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL3146547 | 0.88 | PRKCB (1.00) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| Hydrochloric Acid SCHEMBL3155547 | 0.87 | PRKCB (0.98) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL3158797 | 0.84 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL6422277 | 0.84 | PRKCA (1.00) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL3151388 | 0.84 | PRKCG (0.78) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL27683415 | 0.83 | PRKCG (0.71) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL30958440 | 0.83 | PRKCA (0.70) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL6423238 | 0.83 | PRKCG (1.00) | PRKCAPRKCGPRKCBPRKCECAMK2D | |
| SCHEMBL30319849 | 0.82 | CCNE2 (1.00) | PRKCACDK2CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179175-A1 | USE OF PKC INHIBITORS IN OCULAR DISEASES | SIVAK JEREMY M | 2010-07-15 | — | — | US | claimed |
| US-20100075997-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | KORN ALEXANDER | 2010-03-25 | — | — | US | claimed |
| EP-2056831-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| US-20090062301-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | MAIBUCHER AXEL | 2009-03-05 | — | — | US | claimed |
| EP-2004178-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2008024734-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| US-20070232658-A1 | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction | WAGNER JURGEN | 2007-10-04 | — | — | US | claimed |
| WO-2007107318-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | claimed |
| EP-1734952-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | Novartis AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097108-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| US-20100179175-A1 | USE OF PKC INHIBITORS IN OCULAR DISEASES | SIVAK JEREMY M | 2010-07-15 | — | — | US | disclosed |
| US-20100075997-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | KORN ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| EP-2056831-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| US-20090062301-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | MAIBUCHER AXEL | 2009-03-05 | — | — | US | disclosed |
| EP-2004178-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008024734-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| US-20070232658-A1 | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction | WAGNER JURGEN | 2007-10-04 | — | — | US | disclosed |
| WO-2007107318-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| EP-1734952-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097108-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179175-A1 | USE OF PKC INHIBITORS IN OCULAR DISEASES | PRKCH, PRKAR2B, PRKCB | PRKCA 5/4885PRKCG 7/4885PRKCB 3/4885 |
| US-20100075997-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | PRKAR2B, PRKCB, PRKCA | PRKCA 3/4885PRKCG 6/4885PRKCB 2/4885 |
| US-20070232658-A1 | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction | PRKCA, PRKCB, PRKCG | PRKCA 1/4885PRKCG 3/4885PRKCB 2/4885 |
| US-20090062301-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | JAK3, PRKD3, JAK1 | PRKCA 7/4885PRKCG 27/4885PRKCB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.